Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07645157 Sertraline Hydrochloride Depressive Disorder, Major Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07645157 clinical trial report covering Sertraline Hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07645300 Spironolactone Hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07645300 clinical trial report covering Spironolactone, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07644312 Nivolumab/Relatlimab WHO Grade III Mixed Glioma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07644312 clinical trial report covering Nivolumab/Relatlimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07648745 Cediranib Intestinal Obstruction Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07648745 clinical trial report covering Cediranib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07646717 Irinotecan Hydrochloride Lioposome Intrahepatic Cholangiocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07646717 clinical trial report covering Irinotecan Hydrochloride Lioposome, Phase 2, endpoints, sponsor, geography, readout timing and development white
Latest Hotspot
8 min read
NCT07647289 Enfortumab Vedotin-ejfv Locally Advanced Bladder Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07647289 clinical trial report covering Enfortumab Vedotin-ejfv, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07647263 Trastuzumab Rezetecan HER2 Positive Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07647263 clinical trial report covering Trastuzumab Rezetecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07647016 Trastuzumab Hormone receptor positive HER2 negative breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07647016 clinical trial report covering Trastuzumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07646613 Dihydroergotamine Mesylate Migraine Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07646613 clinical trial report covering Dihydroergotamine Mesylate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600126751 Carboplatin Renal Pelvis and Ureter Urothelial Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
ChiCTR2600126751 clinical trial report covering Carboplatin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07647133 SAL-0140 Chronic Kidney Diseases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07647133 clinical trial report covering SAL-0140, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07648251 Furosemide Pre-Eclampsia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07648251 clinical trial report covering Furosemide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.